Virios Therapeutics: FDA alignment on Phase 3 fibromyalgia and Phase 2 Long-COVID endpoint clarity

Dogwood Therapeutics, Inc.

FDA agreed on Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia treatment.
FDA accepted fatigue as primary endpoint and orthostatic intolerance as key secondary for IMC-2 Long-COVID Phase 2 study.
Company provided unrestricted grant to Bateman Horne Center for placebo-controlled study of up to 60 LC patients on IMC-2.
New international patent application filed for IMC-2 as treatment for Long-COVID and fatigue conditions.
Company has capital to support operations into Q4 2024; exploring M&A opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.